Amneal Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(unaudited; in thousands, except per share amounts)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $197,656 | $282,029 |
| Restricted cash | 4,174 | 28,842 |
| Trade accounts receivable, net | 850,860 | 895,143 |
| Inventories | 641,618 | 606,302 |
| Prepaid expenses and other current assets | 103,091 | 98,395 |
| Related party receivables | 508 | 470 |
| Total current assets | 1,797,907 | 1,911,181 |
| Property, plant and equipment, net | 444,607 | 442,950 |
| Goodwill | 593,800 | 595,470 |
| Intangible assets, net | 534,869 | 563,498 |
| Operating lease right-of-use assets | 46,748 | 38,832 |
| Operating lease right-of-use assets - related party | 14,473 | 15,216 |
| Financing lease right-of-use assets | 52,934 | 53,328 |
| Other assets | 54,880 | 57,805 |
| Total assets | $3,540,218 | $3,678,280 |
| Liabilities and Stockholders’ Deficiency | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $662,975 | $761,316 |
| Current portion of liabilities for legal matters | 10,550 | 43,256 |
| Current portion of long-term debt, net | 6,200 | 6,761 |
| Current portion of operating lease liabilities | 8,922 | 8,668 |
| Current portion of operating lease liabilities - related party | 2,830 | 2,705 |
| Current portion of financing lease liabilities | 3,533 | 3,442 |
| Related party payables - short term | 33,039 | 55,485 |
| Total current liabilities | 728,049 | 881,633 |
| Long-term debt, net | 2,565,558 | 2,565,115 |
| Operating lease liabilities | 41,101 | 33,233 |
| Operating lease liabilities - related party | 13,467 | 14,195 |
| Financing lease liabilities | 54,876 | 54,927 |
| Related party payables - long term | 456 | 19,132 |
| Liabilities for legal matters - long term | 70,021 | 71,819 |
| Other long-term liabilities | 26,747 | 32,263 |
| Total long-term liabilities | 2,772,226 | 2,790,684 |
| Commitments and contingencies (Notes 3, 16 and 18) | ||
| Redeemable non-controlling interests | 85,912 | 77,292 |
| Stockholders’ Deficiency | ||
| Preferred stock, $0.01 par value, 2,000 shares authorized at both March 31, 2026 and December 31, 2025; none issued at both March 31, 2026 and December 31, 2025 | — | — |
| Class A common stock, $0.01 par value, 900,000 shares authorized at both March 31, 2026 and December 31, 2025; 318,998 and 314,565 shares issued at March 31, 2026 and December 31, 2025, respectively | 3,190 | 3,146 |
| Class B common stock, $0.01 par value, 300,000 shares authorized at both March 31, 2026 and December 31, 2025; none issued at both March 31, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital | 536,299 | 571,794 |
| Stockholders’ accumulated deficit | (472,749) | (535,005) |
| Accumulated other comprehensive loss | (112,151) | (110,729) |
| Total Amneal Pharmaceuticals, Inc. stockholders’ deficiency | (45,411) | (70,794) |
| Non-controlling interests | (558) | (535) |
| Total stockholders’ deficiency | (45,969) | (71,329) |
| Total liabilities and stockholders’ deficiency | $3,540,218 | $3,678,280 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.